Merck KGaA Anticipates Challenging Year Amid Generic Drug Competition

Merck KGaA has projected a difficult year ahead, with potential declines in profits due to increased generic competition affecting its multiple sclerosis medication, Mavenclad. Bloomberg posted on X, highlighting the impact on Merck's health care division as it faces challenges from generic alternatives. The company is preparing for a period of reduced financial performance as it navigates the competitive pharmaceutical landscape. This forecast underscores the pressures faced by pharmaceutical companies in maintaining market share against generic competitors source: https://www.binance.com/en/square/post/298191262658594?utm_source=BinanceNewsRSS